Immunotherapy after chemo-radiation shows promise for lung cancer patients
NCT ID NCT07050472
First seen Feb 12, 2026 · Last updated May 12, 2026 · Updated 10 times
Summary
This study looked at 45 people with limited-stage small-cell lung cancer who received the immunotherapy drug durvalumab after standard chemoradiotherapy. The goal was to see how long the cancer stayed under control and how safe the treatment was. Results from this real-world analysis help doctors understand if adding durvalumab can delay cancer progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University Cancer Hospital and Institute
Beijing, Beijing Municipality, 100142, China
Conditions
Explore the condition pages connected to this study.